首页> 外文期刊>中华医学杂志(英文版) >Ranibizumab Plus Combined Surgery for Treatment of Neovascular Glaucoma with Vitreous Hemorrhage
【24h】

Ranibizumab Plus Combined Surgery for Treatment of Neovascular Glaucoma with Vitreous Hemorrhage

机译:雷尼单抗加联合手术治疗玻璃体腔出血的新生血管性青光眼

获取原文
获取原文并翻译 | 示例
           

摘要

Background:Neovascular glaucoma (NVG) is a refractory glaucoma.The management of NVG is very difficult,and it is more difficult when combined with vitreous hemorrhage.The aim of this study was to investigate the effects of ranibizumab plus combined surgery for NVG with vitreous hemorrhage.Methods:A total of 26 eyes of 26 NVG patients with vitreous hemorrhage were recruited in this study.The patients aged from 36 to 63 years with a mean age of 51.97 ± 7.60 years.The mean intraocular pressure (IOP) was 46.38 ± 5.75 mmHg (1 mmHg =0.133 kPa) while being treated with the maximum medical therapy.The mean best-corrected visual acuities converted to logarithm of the minimum angle of resolution (logMAR BCVA) was 2.62 ± 0.43.All the patients underwent intravitreal injection of 0.5 mg (0.05 ml) ranibizumab combined with pars plana vitrectomy (PPV),pars plana lensectomy (PPL) with a preserved anterior capsule,panretinal photocoagulation (PRP),and trabeculectomy (intravitreal ranibizumab [IVR] + PPV + PPL + PRP + trabeculectomy).The IOP and logMAR BCVA were the main outcome measures in this study.Results:The follow-up period was 12 months.The mean postoperative IOPs were 26.38 ± 3.75 mmHg,21.36 ± 3.32 mmHg,1 8.57 ± 3.21 mmHg,and 16.68 ± 2.96 mmHg,respectively at 7 days,1 month,3 months,and 12 months after PPV + PPL + PRP + trabeculectomy.At the last follow-up,the mean IOP was significantly lower than the preoperative one (t =6.612,P =0.001).At 7 days,1 month,3 months,and 12 months after PPV + PPL + PRP + trabeculectomy,the mean logMAR BCVA were 1.30 ± 0.36,1.29 ± 0.37,1.29 ± 0.39,and 1.26 ± 0.29,respectively.At the last follow-up,the mean logMAR BCVA was significantly improved,and the difference was statistically significant compared with preoperative one (t =6.133,P =0.002).The logMAR BCVA improved in 22 eyes (84.62%),and remained stable in 4 eyes (15.38%).The neovascularization in the iris and the angle regressed significantly in all patients 7 days after ranibizumab injection.No serious complications occurred during 12 months of the study.Conclusions:IVR + PPV + PPL + PRP + trabeculectomy can control IOP well and improve BCVA without severe complication for NVG patients with vitreous hemorrhage.
机译:背景:新生血管性青光眼(NVG)是难治性青光眼,NVG的治疗非常困难,合并玻璃体出血更难。本研究的目的是研究兰尼单抗联合玻璃体腔NVG联合手术的效果。方法:本研究共纳入26例NVG玻璃体出血患者的26只眼,年龄36至63岁,平均年龄51.97±7.60岁,平均眼压(IOP)为46.38±接受最大药物治疗时为5.75 mmHg(1 mmHg = 0.133 kPa)。平均最佳矫正视力转换为最小分辨角(logMAR BCVA)的对数为2.62±0.43。 0.5 mg(0.05 ml)雷珠单抗联合保留的前囊膜玻璃体切除术(PPV),保留前囊的帕氏晶状体切除术(PPL),视网膜光凝术(PRP)和小梁切除术(玻璃体内雷珠单抗[IVR] + PP V + PPL + PRP +小梁切除术).IOP和logMAR BCVA是本研究的主要预后指标。结果:随访期为12个月。平均术后IOP为26.38±3.75 mmHg,21.36±3.32 mmHg,1 PPV + PPL + PRP +小梁切除术后7天,1个月,3个月和12个月分别为8.57±3.21 mmHg和16.68±2.96 mmHg。在最后一次随访时,平均IOP显着低于术前PPV + PPL + PRP +小梁切除术后7天,1个月,3个月和12个月时,平均logMAR BCVA为1.30±0.36,1.29±0.37,1.29±0.39,t(6.612,P = 0.001)。和分别为1.26±0.29。在最后一次随访中,平均logMAR BCVA显着改善,与术前相比差异有统计学意义(t = 6.133,P = 0.002)。logMAR BCVA改善了22眼(兰尼单抗注射后7天,患者的4眼(15.38%)保持稳定。虹膜的新血管形成和角度均明显消退。结论:IVR + PPV + PPL + PRP +小梁切除术可以很好地控制IOP并改善BCVA,而无严重并发症的玻璃体出血的NVG患者。

著录项

  • 来源
    《中华医学杂志(英文版)》 |2015年第15期|2078-2083|共6页
  • 作者单位

    Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China;

    Department of Medical Equipment, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China;

    Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China;

    Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China;

    Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号